Biosimulation is a computer-aided mathematical simulation of biological processes and systems and thus is an integral part of systems biology. The global Biosimulation market is expected to witness significant growth in the next few years. This growth is due to technological innovations and research activities in various sides of the medical sector. Additionally, the development of new drugs for various medical diseases and conditions has been occurring in the past few years which raises the demand for biosimulation. This key fact probably drives the growth of the biosimulation market during the forecast period.
Moreover, presently drug development companies and researchers are mainly focusing to find the most effective way to bridge the gap between clinical medicine & drug development and patient response. Also, progressions in software technology and the arrival of artificial intelligence are expected to create a positive influence on the overall growth of the global biosimulation market in the coming years.
On the other hand, factors such as a lack of standardization in biosimulation and the shortage of skilled experts are hampering the growth of the global biosimulation market. In addition, biosimulation uses a variety of models, tools, and languages for processing and capturing many different features of biological processes. Also, the bodies governing it are yet to standardize the use of biosimulation technologies in the process of drug development and discovery. This fact will be creating new opportunities for market development in the coming years.
Biosimulation Market Segment Overview
Based on offering type, the software segment is expected to account for the largest market share in the market. This can be attributed to the increasing adoption of biosimulation software by pharmaceutical and research organizations and the growing R&D investment for pharmaceutical research. Furthermore, the Drug Discovery segment is the fastest-growing segment in the market. Increasing usage of biosimulation and modeling technologies in drug discovery can be attributed to an upsurge in the usage of molecular modeling for the identification of effective compounds that help to improve efficiency and reduce drug toxicity. Moreover, the role of molecular dynamics simulation in drug discovery propels the segment.
Biosimulation Market Regional Overview
North America commanded a major share of the market and is predictable to maintain its supremacy over the forecast period. This is due to increasing collaborations by key players for improving drug discovery capabilities, rising R&D investment by pharmaceutical and biotechnology companies, and growing use of personalized medicines in this region. Similarly, Asia Pacific is expected to expand with an impressive CAGR over the forecast period. The growth of the market in the region can be attributed to the significant demand for innovative drugs, increasing the number of regulatory agencies adopting biosimulation, and rising research activities for life sciences, due to favorable government policies.
Biosimulation Market Competitor overview
· In June 2020, Certara®, the global leader in biosimulation, announced the launch of version 8.3 of its Phoenix™ platform, the industry gold standard in pharmacokinetic/ pharmacodynamic (PK/PD) and toxicokinetic modeling and simulation software. Version 8.3 delivers new features to drive efficiencies and quality and save valuable time.
· In August 2020, Certara®, the global leader in biosimulation, announced the development of a new biosimulation platform for COVID-19 vaccines and major enhancements in its Immunogenicity and Immuno-oncology QSP platforms. Certara has partnered with leading, global pharmaceutical companies on these advancements to help de-risk and speed up drug discovery and development.
Biosimulation Market, Key Players
· Certara, Dassault Systèmes S.A.
· Schrödinger, Inc.
· Simulations Plus, Inc.
· Rhenovia Pharma
· Advanced Chemistry Development, Inc.
· Insilico Biotechnology AG
· Physiomics plc
· Genedata AG
· Rosa & Co. LLC.
Biosimulation Market Segmentation
Biosimulation Market, By Offering Type
- software
- PK/PD modeling & simulation
- PBPK modeling & simulation
- Trial Simulators
- Molecular Modeling
- Others
- services
- Drug Discovery
- Target Identification & Validation
- Lead Identification & Optimization
- Drug Development
- Pre-Clinical Testing
- Clinical Trial
- Others
· Contract Research Organization
· Pharmaceutical & Biotechnology Companies
· Research Institutes
· Regulatory Institutes
· Others
Biosimulation Market, By Region
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Biosimulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Offering Type
- 5.2.1. software
- 5.2.1.1. PK/PD modeling & simulation
- 5.2.1.2. PBPK modeling & simulation
- 5.2.1.3. Trial Simulators
- 5.2.1.4. Molecular Modeling
- 5.2.1.5. Others
- 5.2.2. services
- 5.2.1. software
- 5.3. Market Analysis, Insights and Forecast – By Application
- 5.3.1. Drug Discovery
- 5.3.1.1. Target Identification & Validation
- 5.3.1.2. Lead Identification & Optimization
- 5.3.2. Drug Development
- 5.3.2.1. Pre-Clinical Testing
- 5.3.2.2. Clinical Trial
- 5.3.3. Others
- 5.3.1. Drug Discovery
- 5.4. Market Analysis, Insights and Forecast – By End User
- 5.4.1. Contract Research Organization
- 5.4.2. Pharmaceutical & Biotechnology Companies
- 5.4.3. Research Institutes
- 5.4.4. Regulatory Institutes
- 5.4.5. Others
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Latin America
- 5.5.3. Europe
- 5.5.4. Asia Pacific
- 5.5.5. Middle East and Africa
6. North America Biosimulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Offering Type
- 6.2.1. software
- 6.2.1.1. PK/PD modeling & simulation
- 6.2.1.2. PBPK modeling & simulation
- 6.2.1.3. Trial Simulators
- 6.2.1.4. Molecular Modeling
- 6.2.1.5. Others
- 6.2.2. services
- 6.2.1. software
- 6.3. Market Analysis, Insights and Forecast – By Application
- 6.3.1. Drug Discovery
- 6.3.1.1. Target Identification & Validation
- 6.3.1.2. Lead Identification & Optimization
- 6.3.2. Drug Development
- 6.3.2.1. Pre-Clinical Testing
- 6.3.2.2. Clinical Trial
- 6.3.3. Others
- 6.3.1. Drug Discovery
- 6.4. Market Analysis, Insights and Forecast – By End User
- 6.4.1. Contract Research Organization
- 6.4.2. Pharmaceutical & Biotechnology Companies
- 6.4.3. Research Institutes
- 6.4.4. Regulatory Institutes
- 6.4.5. Others
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Latin America Biosimulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Offering Type
- 7.2.1. software
- 7.2.1.1. PK/PD modeling & simulation
- 7.2.1.2. PBPK modeling & simulation
- 7.2.1.3. Trial Simulators
- 7.2.1.4. Molecular Modeling
- 7.2.1.5. Others
- 7.2.2. services
- 7.2.1. software
- 7.3. Market Analysis, Insights and Forecast – By Application
- 7.3.1. Drug Discovery
- 7.3.1.1. Target Identification & Validation
- 7.3.1.2. Lead Identification & Optimization
- 7.3.2. Drug Development
- 7.3.2.1. Pre-Clinical Testing
- 7.3.2.2. Clinical Trial
- 7.3.3. Others
- 7.3.1. Drug Discovery
- 7.4. Market Analysis, Insights and Forecast – By End User
- 7.4.1. Contract Research Organization
- 7.4.2. Pharmaceutical & Biotechnology Companies
- 7.4.3. Research Institutes
- 7.4.4. Regulatory Institutes
- 7.4.5. Others
- 7.5. Market Analysis, Insights and Forecast – By Country
- 7.5.1. Brazil
- 7.5.2. Mexico
- 7.5.3. Rest of Latin America
8. Europe Biosimulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Offering Type
- 8.2.1. software
- 8.2.1.1. PK/PD modeling & simulation
- 8.2.1.2. PBPK modeling & simulation
- 8.2.1.3. Trial Simulators
- 8.2.1.4. Molecular Modeling
- 8.2.1.5. Others
- 8.2.2. services
- 8.2.1. software
- 8.3. Market Analysis, Insights and Forecast – By Application
- 8.3.1. Drug Discovery
- 8.3.1.1. Target Identification & Validation
- 8.3.1.2. Lead Identification & Optimization
- 8.3.2. Drug Development
- 8.3.2.1. Pre-Clinical Testing
- 8.3.2.2. Clinical Trial
- 8.3.3. Others
- 8.3.1. Drug Discovery
- 8.4. Market Analysis, Insights and Forecast – By End User
- 8.4.1. Contract Research Organization
- 8.4.2. Pharmaceutical & Biotechnology Companies
- 8.4.3. Research Institutes
- 8.4.4. Regulatory Institutes
- 8.4.5. Others
- 8.5. Market Analysis, Insights and Forecast – By Country
- 8.5.1. UK
- 8.5.2. Germany
- 8.5.3. France
- 8.5.4. Italy
- 8.5.5. Spain
- 8.5.6. Russia
- 8.5.7. Rest of Europe
9. Asia Pacific Biosimulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Offering Type
- 9.2.1. software
- 9.2.1.1. PK/PD modeling & simulation
- 9.2.1.2. PBPK modeling & simulation
- 9.2.1.3. Trial Simulators
- 9.2.1.4. Molecular Modeling
- 9.2.1.5. Others
- 9.2.2. services
- 9.2.1. software
- 9.3. Market Analysis, Insights and Forecast – By Application
- 9.3.1. Drug Discovery
- 9.3.1.1. Target Identification & Validation
- 9.3.1.2. Lead Identification & Optimization
- 9.3.2. Drug Development
- 9.3.2.1. Pre-Clinical Testing
- 9.3.2.2. Clinical Trial
- 9.3.3. Others
- 9.3.1. Drug Discovery
- 9.4. Market Analysis, Insights and Forecast – By End User
- 9.4.1. Contract Research Organization
- 9.4.2. Pharmaceutical & Biotechnology Companies
- 9.4.3. Research Institutes
- 9.4.4. Regulatory Institutes
- 9.4.5. Others
- 9.5. Market Analysis, Insights and Forecast – By Country
- 9.5.1. China
- 9.5.2. India
- 9.5.3. Japan
- 9.5.4. Australia
- 9.5.5. South East Asia
- 9.5.6. Rest of Asia Pacific
10. Middle East & Africa Biosimulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 10.1. Key Findings / Summary
- 10.2. Market Analysis, Insights and Forecast – By Offering Type
- 10.2.1. software
- 10.2.1.1. PK/PD modeling & simulation
- 10.2.1.2. PBPK modeling & simulation
- 10.2.1.3. Trial Simulators
- 10.2.1.4. Molecular Modeling
- 10.2.1.5. Others
- 10.2.2. services
- 10.2.1. software
- 10.3. Market Analysis, Insights and Forecast – By Application
- 10.3.1. Drug Discovery
- 10.3.1.1. Target Identification & Validation
- 10.3.1.2. Lead Identification & Optimization
- 10.3.2. Drug Development
- 10.3.2.1. Pre-Clinical Testing
- 10.3.2.2. Clinical Trial
- 10.3.3. Others
- 10.3.1. Drug Discovery
- 10.4. Market Analysis, Insights and Forecast – By End User
- 10.4.1. Contract Research Organization
- 10.4.2. Pharmaceutical & Biotechnology Companies
- 10.4.3. Research Institutes
- 10.4.4. Regulatory Institutes
- 10.4.5. Others
- 10.5. Market Analysis, Insights and Forecast – By Country
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Company Market Share Analysis, 2018
- 11.2. Key Industry Developments
- 11.3. Company Profile
- 11.4. Certara, Dassault Systèmes S.A.
- 11.4.1. Business Overview
- 11.4.2. Segment 1 & Service Offering
- 11.4.3. Overall Revenue
- 11.4.4. Geographic Presence
- 11.4.5. Recent Development
- 11.5. Schrödinger, Inc.
- 11.6. Simulations Plus, Inc.
- 11.7. Rhenovia Pharma
- 11.8. Advanced Chemistry Development, Inc.
- 11.9. Insilico Biotechnology AG
- 11.10. Physiomics plc
- 11.11. Genedata AG
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
